The year 2025 marks a definitive transition in the history of pharmaceutical R&D. We have moved from isolated experiments to verticalized, domain-specific AI infrastructures operating at enterprise scale.
Our latest report explores how the industry is finally challenging “Eroom’s Law” through a potential doubling of end-to-end R&D productivity15. Key highlights include the rise of the “Lab-in-a-Loop” standard at Roche/Genentech and the strategic pivot toward biologics driven by the Inflation Reduction Act16161616. For C-suite and R&D directors, the report offers a roadmap for transitioning to “AI Factories” and adopting federated learning architectures to preserve IP while maximizing innovation.